verteporfin

(redirected from Benzoporphyrin derivative)

verteporfin

 [ver″tĕ-por´fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathologic myopia; the agent is then activated by light of a specific wavelength in the presence of oxygen, and causes local damage to the neovascular endothelium followed by vessel occlusion; it is administered intravenously prior to irradiation of the lesion with light from a compatible laser.

ver·te·por·fin

(vĕr-tē-pōr'fin),
Photosensitizer agent used in photodynamic therapy to treat choroidal neovascularization secondary to age related macular degeneration.

verteporfin

/ver·te·por·fin/ (ver″tĕ-por´fin) a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid; used, together with appropriate laser irradiation of the lesion, in the treatment of neovascularization due to disciform macular degeneration, to presumed ocular histoplasmosis, or to pathologic myopia.

verteporfin

[ver′tĕ-por′fin]
a photosensitizing agent that accumulates preferentially in neovasculature, including that in the choroid, such as occurs in age-related macular degeneration, ocular histoplasmosis, or pathological myopia. The agent is then activated by light of a specific wavelength in the presence of oxygen and causes local damage to the neovascular endothelium followed by vessel occlusion. It is administered intravenously before irradiation of the lesion with light from a compatible laser.
Mentioned in ?
References in periodicals archive ?
Four photosensitizing drugs, Photofring, Texas Red, a benzoporphyrin derivative monoacid (BPD), and lutetium texaphyrin (LuTex) were tested to see if they were substrates of the MDR-1 multidrug resistor pump, or if they could be used in PDT.
Analysis of Photosensitizer Uptake in Roach Malpighian Tubules
Quadra Logic is today testing an even stronger free radical-releasing drug called benzoporphyrin derivative, or BPD, which is also activated by light.
Photodynamic therapy treats cancers, possibly AIDS
QLT's second-generation product, Benzoporphyrin derivative (BPD-MA) is undergoing clinical trials for the treatment of age-related macular degeneration, the leading cause of blindness in the elderly.
Photofrin launched in U.S. market
In a multi-center Phase I/II clinical trial, co-sponsored by QLT and CIBA Vision, researchers presented preliminary ocular safety and proof-of-principle data suggesting that the light-activated drug, Benzoporphyrin derivative (BPD), can selectively close abnormal blood vessels in the eye that are associated with the severe or "wet" form of Age-related Macular Degeneration (AMD) without causing vision loss associated with currently available treatments.
QLT PhotoTherapeutics - Light-Activated Drug May Offer New Treatment for Leading Cause of Blindness Among Elderly
The Company has several drugs under development, including clinical trials for Benzoporphyrin derivative (BPD), a second-generation photosensitizer.
QLT PhotoTherapeutics to Offer 3,000,000 Common Shares
The Company has several drugs under development, including the approved product PHOTOFRIN(R) and clinical trials for Benzoporphyrin derivative, a second-generation photosensitizer.
QLT PhotoTherapeutics - Sanofi Winthrop Completes Equity Investment in QLT
The company has several drugs under development, including Benzoporphyrin derivative, a second-generation photosensitizer, currently in clinical trials.
FDA Gives Marketing Clearance to Innovative Laser-Drug Cancer Treatment; Laserscope to Market Lasers and Devices for New QLT/Sanofi Winthrop Collaboration
BOSTON, MA--(BUSINESS WIRE)--MAY 2, 1995--QUADRA LOGIC(TSE: QLT NASDAQ: QLTIF) Researchers at the Massachusetts Eye and Ear Infirmary and Harvard Medical School have commenced a Phase I safety and proof- of-concept clinical study involving the use of the light-activated drug, Benzoporphyrin derivative (BPD), as a potential treatment for Age-related Macular Degeneration.
CIBA VISION AND QLT BEGIN U.S. CLINICAL TRIAL OF BPD FOR EYE DISEASE
BOSTON--(BUSINESS WIRE)--May 2, 1995--Researchers at the Massachusetts Eye and Ear Infirmary and Harvard Medical School have commenced a Phase I safety and proof- of-concept clinical study involving the use of the light-activated drug, Benzoporphyrin derivative (BPD), as a potential treatment for Age-related Macular Degeneration.
Ciba-Vision and QLT begin U.S. clinical trial of BPD for eye disease
No longer proposed is the granting by QLT to Ciba of an exclusive option to negotiate future rights for cancer and psoriasis applications of QLT's PDT drug, Benzoporphyrin derivative (BPD).
QLT ACQUIRES EXCLUSIVE LICENSE TO CIBA'S PHOTODYNAMIC THERAPY DRUG
Pending clearance of these submissions, human clinical trials will commence in the United States and Germany, using Benzoporphyrin derivative (BPD) to treat AMD.
CIBA VISION AND QUADRA LOGIC TO CO-DEVELOP PHOTODYNAMIC THERAPY FOR EYE DISEASES
11, 1994-- Clinicians in a QLT-sponsored trial have begun using topical formulations of Benzoporphyrin derivative (BPD) activated by Light Emitting Diodes (LEDs) as a potential treatment for moderate- to-severe forms of psoriasis.
QUADRA LOGIC TECHNOLOGIES -- TOPICAL BPD AND LIGHT-EMITTING DIODES TO BE USED IN NEW PSORIASIS TRIAL

Medical browser ?
Full browser ?